What happened with TTRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Turn Therapeutics focuses on GX-03, a topical drug candidate being tested for moderate-to-severe eczema. It is also developing GX-03 for fungal nail infections. These programs remain in development; earlier FDA clearances for devices using the same formulation do not constitute drug approval.
The company keeps drug research and regulatory work in-house while turning to partners to bring medical devices to market. MiMedx holds exclusive rights to develop, manufacture and commercialize FleX in specified markets and uses, and would pay Turn royalties on net sales once commercial sales begin. Medline has licensed Turn’s FDA-cleared antimicrobial gauze and will lead global commercialization of health products developed together using Turn’s PermaFusion formulation platform.
Turn has minimal operating revenue and no products currently available for commercial sale. It relies on additional financing and licensing or collaboration arrangements to fund development. Future income depends on successful trials, the required regulatory approvals or clearances, and partners bringing products to market; Turn cannot commercialize unapproved future products before regulators authorize them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Turn Therapeutics Inc.’s prospects hinge mainly on GX-03 eczema trial results and regulatory approval, while device licensing to MiMedx and Medline offers a separate potential revenue stream.
MiMedx Group, Inc sells wound, burn and surgical-care products and owes Turn Therapeutics Inc. royalties on net sales of products licensed from Turn, including FleX. Watch FleX’s approval progress and licensed-product sales: Turn’s royalties begin with each product’s first commercial sale in each country.
Turn Therapeutics Inc. relies on Medline Inc., a supplier to hospitals and other care providers, to lead global sales and distribution of jointly developed PermaFusion products for professional and consumer health. Medline also licenses Turn’s GX-03 antimicrobial gauze; watch that product’s commercialization and progress on jointly developed products, though the gauze agreement’s financial terms are not disclosed.
MiMedx Group, Inc earningsMDXG
MiMedx Group, Inc.'s report can show whether it is advancing Turn Therapeutics Inc.'s licensed FleX product toward sales that could generate royalties for Turn.
Separate FleX's approval or launch progress from actual product sales. Turn earns royalties on FleX only after its first commercial sale in a country, so growth in MiMedx's overall wound-care business does not establish FleX sales. A disclosed launch and sales would establish a starting point for Turn's royalties; overall growth without FleX launch or sales progress would mean those sales-based royalties have not begun.
Turn Therapeutics Inc. earningsThis company
Turn Therapeutics Inc.'s report will show whether income from licensed products is beginning to help cover the cash it spends developing GX-03 and other drug candidates.
Read revenue alongside cash used in operations and the cash balance. Turn earns mid-single-digit royalties on net sales of FleX only after commercial sales begin in each country; it has also previously deferred license revenue because the timing and outcome of the FDA process could not be reasonably estimated. Royalties from actual sales alongside lower operating cash use would show the partnerships are beginning to support development. Little revenue with continued cash use would mean Turn still depends on outside financing.
